sb-223245 and Disease-Models--Animal

sb-223245 has been researched along with Disease-Models--Animal* in 2 studies

Other Studies

2 other study(ies) available for sb-223245 and Disease-Models--Animal

Article	Year
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorganic & medicinal chemistry letters, 1999, Jul-05, Volume: 9, Issue:13 A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral bioavailability in rats, and is orally active in vivo in the ovariectomized rat model of osteoporosis. Topics: Acetates; Administration, Oral; Aminopyridines; Animals; Benzodiazepinones; Biological Availability; Disease Models, Animal; Kinetics; Osteoporosis; Rats; Receptors, Vitronectin; Time Factors	1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model. Bioorganic & medicinal chemistry letters, 1998, Nov-17, Volume: 8, Issue:22 In the 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists, a compound containing an imidazopyridine arginine mimetic was discovered which had sufficient potency and i.v. pharmacokinetics for demonstration of efficacy in a rat restenosis model. Topics: Angioplasty, Balloon, Coronary; Animals; Benzodiazepines; Coronary Disease; Disease Models, Animal; Imidazoles; Pyridines; Rats; Receptors, Vitronectin	1998

Article

Year

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

Bioorganic & medicinal chemistry letters, 1999, Jul-05, Volume: 9, Issue:13

A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral bioavailability in rats, and is orally active in vivo in the ovariectomized rat model of osteoporosis.

Topics: Acetates; Administration, Oral; Aminopyridines; Animals; Benzodiazepinones; Biological Availability; Disease Models, Animal; Kinetics; Osteoporosis; Rats; Receptors, Vitronectin; Time Factors

1999

Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.

Bioorganic & medicinal chemistry letters, 1998, Nov-17, Volume: 8, Issue:22

In the 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists, a compound containing an imidazopyridine arginine mimetic was discovered which had sufficient potency and i.v. pharmacokinetics for demonstration of efficacy in a rat restenosis model.

Topics: Angioplasty, Balloon, Coronary; Animals; Benzodiazepines; Coronary Disease; Disease Models, Animal; Imidazoles; Pyridines; Rats; Receptors, Vitronectin

1998